International Influenza Surveillance and Response System (GISRS) (WHO, accessed 1 October 2023); https://www.who.int/initiatives/global-influenza-surveillance-and-response-system
Gaymard, A., Le Briand, N., Frobert, E., Lina, B. & Escuret, V. Practical stability between neuraminidase and haemagglutinin in influenza viruses. Clin. Microbiol. Infect. 22, 975–983 (2016).
Petrova, V. N. & Russell, C. A. The evolution of seasonal influenza viruses. Nat. Rev. Microbiol. 16, 47–60 (2018).
Telenti, A. et al. After the pandemic: views on the long run trajectory of COVID-19. Nature 596, 495–504 (2021).
Lewnard, J. A. & Cobey, S. Immune historical past and influenza vaccine effectiveness. Vaccines 6, E28 (2018).
Smith, D. J. et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305, 371–376 (2004).
Henry, C., Palm, A.-Ok. E., Krammer, F. & Wilson, P. C. From unique antigenic sin to the common influenza virus vaccine. Tendencies Immunol. 39, 70–79 (2018).
Biswas, A., Chakrabarti, A. Ok. & Dutta, S. Present challenges: from the trail of ‘unique antigenic sin’ in the direction of the event of common flu vaccines. Int. Rev. Immunol. 39, 21–36 (2020).
Yewdell, J. W. & Santos, J. J. S. Unique antigenic sin: how unique? How sinful? Chilly Spring Harb. Perspect. Med. 11, a038786 (2021).
Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and health. Nat. Rev. Microbiol. 21, 162–177 (2023).
Lan, J. et al. Construction of the SARS-CoV-2 spike receptor-binding area sure to the ACE2 receptor. Nature 581, 215–220 (2020).
Piccoli, L. et al. Mapping neutralizing and immunodominant websites on the SARS-CoV-2 spike receptor-binding area by structure-guided high-resolution serology. Cell 183, 1024–1042 (2020).
Duchene, S. et al. Temporal sign and the phylodynamic threshold of SARS-CoV-2. Virus Evol. 6, veaa061 (2020).
Monitoring SARS-CoV-2 Variants (WHO, accessed 1 October 2023); https://www.who.int/actions/tracking-SARS-CoV-2-variants
Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron an infection. Nature 608, 593–602 (2022).
Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186, 279–286 (2023).
Simon-Loriere, E. & Schwartz, O. In the direction of SARS-CoV-2 serotypes? Nat. Rev. Microbiol. 20, 187–188 (2022).
Goldstein, S. A., Brown, J., Pedersen, B. S., Quinlan, A. R. & Elde, N. C. In depth recombination-driven coronavirus diversification expands the pool of potential pandemic pathogens. Genome Biol. Evol.14, evac161 (2022).
Kurhade, C. et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat. Med. 29, 344–347 (2022).
Chalkias, S. et al. Unique SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: part 2/3 trial interim outcomes. Nat. Med. 29, 2325–2333 (2023).
Khoury, D. S. et al. Predicting the efficacy of variant-modified COVID-19 vaccine boosters. Nat. Med. 29, 574–578 (2023).
Chemaitelly, H. et al. Immune imprinting and safety in opposition to repeat reinfection with SARS-CoV-2. N. Engl. J. Med. 387, 1716–1718 (2022).
Aguilar-Bretones, M., Fouchier, R. A. M., Koopmans, M. P. G. & Nierop, G. Pvan Influence of antigenic evolution and unique antigenic sin on SARS-CoV-2 immunity. J. Clin. Make investments. 133, e162192 (2023).
Offit, P. A. Bivalent COVID-19 vaccines—a cautionary story. N. Engl. J. Med. 388, 481–483 (2023).
Hoehl, S. & Ciesek, S. Recalling ancestral SARS-CoV-2 variants: is it an unique sin with advantages? Lancet Infect. Dis. 23, 272–273 (2023).
Francis, T. On the doctrine of unique antigenic sin. Proc. Am. Philos. Soc. 104, 572–578 (1960).
Murray, S. M. et al. The influence of pre-existing cross-reactive immunity on SARS-CoV-2 an infection and vaccine responses. Nat. Rev. Immunol. 23, 304–316 (2023).
Ng, Ok. W. et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in people. Science 370, 1339–1343 (2020).
Rajendran, M. et al. Evaluation of anti-influenza virus neuraminidase antibodies in kids, adults and the aged by ELISA and enzyme inhibition: proof for unique antigenic sin. mBio 8, e02281-16 (2017).
Rothman, A. L. Immunity to Dengue virus: a story of unique antigenic sin and tropical cytokine storms. Nat. Rev. Immunol. 11, 532–543 (2011).
Tripp, R. A. & Energy, U. F. Unique antigenic sin and respiratory syncytial virus vaccines. Vaccines 7, 107 (2019).
Baraniak, I., Kern, F., Holenya, P., Griffiths, P. & Reeves, M. Unique antigenic sin shapes the immunological repertoire evoked by human cytomegalovirus glycoprotein B/MF59 vaccine in seropositive recipients. J. Infect. Dis. 220, 228–232 (2019).
Lessler, J. et al. Proof for antigenic seniority in influenza A (H3N2) antibody responses in Southern China. PLoS Pathog. 8, e1002802 (2012).
Shrock, E. et al. Viral epitope profiling of COVID-19 sufferers reveals cross-reactivity and correlates of severity. Science 370, eabd4250 (2020).
Woudenberg, T. et al. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in kids and adults in north-eastern France. eBioMedicine 70, 103495 (2021).
Aguilar-Bretones, M. et al. Seasonal coronavirus-specific B cells with restricted SARS-CoV-2 cross-reactivity dominate the IgG response in extreme COVID-19. J. Clin. Make investments. 131, e150613 (2021).
McNaughton, A. L. et al. Deadly COVID-19 outcomes are related to an antibody response focusing on epitopes shared with endemic coronaviruses. JCI Perception 7, e156372 (2022).
Anderson, E. M. et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 an infection however not related to safety. Cell 184, 1858–1864 (2021).
Prévost, J. et al. Cross-sectional analysis of humoral responses in opposition to SARS-CoV-2 spike. Cell Rep. Med. 1, 100126 (2020).
Lv, H. et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep. 31, 107725 (2020).
Yuan, M. et al. A extremely conserved cryptic epitope within the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630–633 (2020).
Tan, C.-W. et al. Pan-Sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 survivors. N. Engl. J. Med. 385, 1401–1406 (2021).
Zar, H. J. et al. Pure and hybrid immunity following 4 COVID-19 waves: a potential cohort examine of moms in South Africa. eClinicalMedicine 53, 101655 (2022).
Goel, R. R. et al. Environment friendly recall of Omicron-reactive B cell reminiscence after a 3rd dose of SARS-CoV-2 mRNA vaccine. Cell 185, 1875–1887 (2022).
Röltgen, Ok. et al. Immune imprinting, breadth of variant recognition, and germinal middle response in human SARS-CoV-2 an infection and vaccination. Cell 185, 1025–1040 (2022).
Kaku, C. I. et al. Recall of preexisting cross-reactive B cell reminiscence after Omicron BA.1 breakthrough an infection. Sci. Immunol. 7, eabq3511 (2022).
Hoffmann, M. et al. Impact of hybrid immunity and bivalent booster vaccination on Omicron sublineage neutralisation. Lancet Infect. Dis. 23, 25–28 (2023).
Chu, L. et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label part 2 trial. Nat. Med. 28, 1042–1049 (2022).
Alsoussi, W. B. et al. SARS-CoV-2 Omicron boosting induces de novo B-cell response in people. Nature 617, 592–598 (2023).
Chalkias, S. et al. Security, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine in opposition to COVID-19: a part 2/3 trial. Nat Med 28, 2388–2397 (2022).
Chalkias, S. et al. A bivalent Omicron-containing booster vaccine in opposition to COVID-19. N. Engl. J. Med. 387, 1279–1291 (2022).
Zou, J. et al. Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1 with bivalent vaccine. N. Engl. J. Med. 388, 854–857 (2023).
Wang, Q. et al. Antibody response to Omicron BA.4–BA.5 bivalent booster. N. Engl. J. Med. 388, 567–569 (2023).
Collier, A. Y. et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N. Engl. J. Med. 388, 565–567 (2023).
Davis-Gardner, M. E. et al. Neutralization in opposition to BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster. N. Engl. J. Med. 388, 183–185 (2023).
Assertion on the antigen composition of COVID-19 vaccines. WHO (18 Might 202); https://www.who.int/information/merchandise/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines
Chalkias, S. et al. Security and immunogenicity of XBB.1.5-containing mRNA vaccines. Preprint at https://doi.org/10.1101/2023.08.22.23293434 (2023).
Pfizer and BioNTech obtain constructive CHMP opinion for Omicron XBB.1.5-adapted COVID-19 vaccine within the European Union. Pfizer (30 August 2023); https://www.pfizer.com/information/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-2
Jones-Grey, E., Robinson, E. J., Kucharski, A. J., Fox, A. & Sullivan, S. G. Does repeated influenza vaccination attenuate effectiveness? A scientific overview and meta-analysis. Lancet Resp. Med. 11, 27–44 (2023).
Gostic, Ok. M. et al. Childhood immune imprinting to influenza A shapes delivery year-specific threat throughout seasonal H1N1 and H3N2 epidemics. PLoS Pathog. 15, e1008109 (2019).
Petrie, J. G. et al. Antibodies in opposition to the present influenza A(H1N1) vaccine pressure don’t defend some people from an infection with up to date circulating influenza A(H1N1) virus strains. J. Infect. Dis. 214, 1947–1951 (2016).
Linderman, S. L. et al. Potential antigenic clarification for atypical H1N1 infections amongst middle-aged adults in the course of the 2013–2014 influenza season. Proc. Natl Acad. Sci. USA 111, 15798–15803 (2014).
Gagnon, A. et al. Age-specific mortality in the course of the 1918 influenza pandemic: unravelling the thriller of excessive younger grownup mortality. PLoS ONE 8, e69586 (2013).
Ma, J., Dushoff, J. & Earn, D. J. D. Age-specific mortality threat from pandemic influenza. J. Theor. Biol. 288, 29–34 (2011).
Gagnon, A. et al. Pandemic paradox: adolescence H2N2 pandemic influenza an infection enhanced susceptibility to demise in the course of the 2009 H1N1 pandemic. mBio 9, e02091-17 (2018).
Gagnon, A., Acosta, J. E., Madrenas, J. & Miller, M. S. Is antigenic sin at all times ‘unique’? Re-examining the proof relating to circulation of a human H1 influenza virus instantly previous to the 1918 Spanish flu. PLoS Pathog. 11, e1004615 (2015).
Simonsen, L. et al. International mortality estimates for the 2009 influenza pandemic from the GLaMOR undertaking: a modeling examine. PLoS Med. 10, e1001558 (2013).
O’Donnell, C. D. et al. People and ferrets with prior H1N1 influenza virus infections don’t exhibit proof of unique antigenic sin after an infection or vaccination with the 2009 pandemic H1N1 influenza virus. Clin. Vaccin. Immunol. 21, 737–746 (2014).
Gostic, Ok. M., Ambrose, M., Worobey, M. & Lloyd-Smith, J. O. Potent safety in opposition to H5N1 and H7N9 influenza by way of childhood hemagglutinin imprinting. Science 354, 722–726 (2016).
Wratil, P. R. et al. Proof for elevated SARS-CoV-2 susceptibility and COVID-19 severity associated to pre-existing immunity to seasonal coronaviruses. Cell Rep. 37, 110169 (2021).
Aran, D., Beachler, D. C., Lanes, S. & Overhage, J. M. Prior presumed coronavirus an infection reduces COVID-19 threat: a cohort examine. J. Infect. 81, 923–930 (2020).
Sagar, M. et al. Current endemic coronavirus an infection is related to less-severe COVID-19. J. Clin. Make investments. 131, e143380 (2021).
Smit, W. L. et al. Heterologous immune responses of serum IgG and secretory IgA in opposition to the spike protein of endemic coronaviruses throughout extreme COVID-19. Entrance. Immunol. 13, 839367 (2022).
Aydillo, T. et al. Immunological imprinting of the antibody response in COVID-19 sufferers. Nat. Commun. 12, 3781 (2021).
Guo, L. et al. Cross-reactive antibody in opposition to human coronavirus OC43 spike protein correlates with illness severity in COVID-19 sufferers: a retrospective examine. Emerg. Microbes Infect. 10, 664–676 (2021).
Woodruff, M. C. et al. Extrafollicular B-cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat. Immunol. 21, 1506–1516 (2020).
Dejnirattisai, W. et al. The antigenic anatomy of SARS-CoV-2 receptor binding area. Cell 184, 2183–2200 (2021).
Kaplonek, P. et al. Early cross-coronavirus reactive signatures of humoral immunity in opposition to COVID-19. Sci. Immunol. 6, eabj2901 (2021).
Pinotti, F. et al. Potential influence of particular person publicity histories to endemic human coronaviruses on age-dependent severity of COVID-19. BMC Med. 19, 19 (2021).
Thompson, R. N. et al. The influence of cross-reactive immunity on the emergence of SARS-CoV-2 variants. Entrance. Immunol. 13, 1049458 (2023).
Hyperlink-Gelles, R. Effectiveness of bivalent mRNA vaccines in stopping symptomatic SARS-CoV-2 an infection—growing neighborhood entry to testing program, United States, September-November 2022. MMWR Morb. Mortal. Wkly Rep. 71, 1526–1530 (2022).
Smith, D. J., Forrest, S., Ackley, D. H. & Perelson, A. S. Variable efficacy of repeated annual influenza vaccination. Proc. Natl Acad. Sci. USA 96, 14001–14006 (1999).
Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response in opposition to 2009 pandemic H1N1 influenza virus an infection. J. Exp. Med. 208, 181–193 (2011).
Cortina-Ceballos, B. et al. Longitudinal evaluation of the peripheral B cell repertoire reveals distinctive results of immunization with a brand new influenza virus pressure. Genome Med. 7, 124 (2015).
Avnir, Y. et al. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies in opposition to influenza A viruses. PLoS Pathog. 10, e1004103 (2014).
Laidlaw, B. J. & Ellebedy, A. H. The germinal centre B-cell response to SARS-CoV-2. Nat. Rev. Immunol. 22, 7–18 (2022).
Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639–644 (2021).
Kim, W. et al. Germinal centre-driven maturation of B-cell response to mRNA vaccination. Nature 604, 141–145 (2022).
Wang, Z. et al. Naturally enhanced neutralizing breadth in opposition to SARS-CoV-2 one yr after an infection. Nature 595, 426–431 (2021).
Wang, Z. et al. Reminiscence B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough an infection in people. J. Exp. Med. 219, e20221006 (2022).
Moriyama, S. et al. Temporal maturation of neutralizing antibodies in COVID-19 convalescent people improves efficiency and breadth to circulating SARS-CoV-2 variants. Immunity 54, 1841–1852 (2021).
Sokal, A. et al. Maturation and persistence of the anti-SARS-CoV-2 reminiscence B cell response. Cell 184, 1201–1213 (2021).
Dugan, H. L. et al. Profiling B cell immunodominance after SARS-CoV-2 an infection reveals antibody evolution to non-neutralizing viral targets. Immunity 54, 1290–1303 (2021).
Muecksch, F. et al. Elevated reminiscence B cell efficiency and breadth after a SARS-CoV-2 mRNA enhance. Nature 607, 128–134 (2022).
Park, Y.-J. et al. Imprinted antibody responses in opposition to SARS-CoV-2 Omicron sublineages. Science 378, 619–627 (2022).
Reynolds, C. J. et al. Immune boosting by B.1.1.529 (Omicron) relies on earlier SARS-CoV-2 publicity. Science 377, eabq1841 (2022).
Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 614, 521–529 (2023).
Quandt, J. et al. Omicron BA.1 breakthrough an infection drives cross-variant neutralization and reminiscence B cell formation in opposition to conserved epitopes. Sci. Immunol. 7, eabq2427 (2022).
Kaku, C. I. et al. Evolution of antibody immunity following Omicron BA.1 breakthrough an infection. Nat. Commun. 14, 2751 (2023).
Reynolds, C. J. et al. Heterologous an infection and vaccination shapes immunity in opposition to SARS-CoV-2 variants. Science 375, 183–192 (2022).
Butler, D. Lengthy-term research will monitor indelible marks of first flu. Nature 569, 464–465 (2019).
Kim, J. H., Skountzou, I., Compans, R. & Jacob, J. Unique antigenic sin responses to influenza viruses. J. Immunol. 183, 3294–3301 (2009).
Fox, A. et al. Opposing results of prior an infection versus prior vaccination on vaccine immunogenicity in opposition to influenza A(H3N2) viruses. Viruses 14, 470 (2022).
Saito, N. et al. Adverse influence of prior influenza vaccination on present influenza vaccination amongst folks contaminated and never contaminated in prior season: a test-negative case-control examine in Japan. Vaccine 35, 687–693 (2017).
Greaney, A. J. et al. Antibodies elicited by mRNA-1273 vaccination bind extra broadly to the receptor binding area than do these from SARS-CoV-2 an infection. Sci. Transl. Med. 13, eabi9915 (2021).
Amanat, F. et al. SARS-CoV-2 mRNA vaccination induces functionally various antibodies to NTD, RBD and S2. Cell 184, 3936–3948 (2021).
Pillai, S. SARS-CoV-2 vaccination washes away unique antigenic sin. Tendencies Immunol. 43, 271–273 (2022).
Kaneko, N. et al. Lack of Bcl-6-expressing T follicular helper cells and germinal facilities in COVID-19. Cell 183, 143–157 (2020).
Buckner, C. M. et al. Interval between prior SARS-CoV-2 an infection and booster vaccination impacts magnitude and high quality of antibody and B cell responses. Cell 185, 4333–4346 (2022).
Worobey, M., Plotkin, S. & Hensley, S. E. Influenza vaccines delivered in early childhood might flip antigenic sin into antigenic blessings. Chilly Spring Harb. Perspect. Med. 10, a038471 (2020).
Bodewes, R. et al. Prevalence of antibodies in opposition to seasonal influenza A and B viruses in kids in Netherlands. Clin. Vaccin. Immunol. 18, 469–476 (2011).
Belshe, R. B. et al. Dwell attenuated versus inactivated influenza vaccine in infants and younger kids. N. Engl. J. Med. 356, 685–696 (2007).
Pilapitiya, D., Wheatley, A. Ok. & Tan, H.-X. Mucosal vaccines for SARS-CoV-2: triumph of hope over expertise. eBioMedicine 92, 104585 (2023).
Meade, P. et al. Antigenic panorama evaluation of people vaccinated with a common influenza virus vaccine candidate reveals induction of cross-subtype immunity. J. Virol. 97, e0107022 (2022).
Krammer, F. The hunt for a common flu vaccine: headless HA 2.0. Cell Host Microbe 18, 395–397 (2015).
Widge, A. T. et al. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in wholesome adults. Sci. Transl. Med. 15, eade4790 (2023).
Andrews, S. F. et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in people. Sci. Transl. Med. 15, eade4976 (2023).
Dai, L. et al. Efficacy and security of the RBD-dimer-based COVID-19 vaccine ZF2001 in adults. N. Engl. J. Med. 386, 2097–2111 (2022).
Hernández-Bernal, F. et al. Security, tolerability and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: a randomised, double-blind, placebo-controlled, part 1-2 medical trial (ABDALA Research). eClinicalMedicine 46, 101383 (2022).
Ng, Ok. W. et al. SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies. Sci. Transl. Med. 14, eabn3715 (2022).
Braet, S. M. et al. Timeline of modifications in spike conformational dynamics in emergent SARS-CoV-2 variants reveal progressive stabilization of trimer stalk with altered NTD dynamics. eLife 12, e82584 (2023).
Nachbagauer, R. et al. A chimeric hemagglutinin-based common influenza virus vaccine strategy induces broad and long-lasting immunity in a randomized, placebo-controlled part I trial. Nat. Med. 27, 106–114 (2021).
Broecker, F. et al. A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from problem with divergent H3N2 strains. npj Vaccines 4, 31 (2019).
Solar, W. et al. Improvement of influenza B common vaccine candidates utilizing the ‘mosaic’ hemagglutinin strategy. J. Virol. 93, e00333-19 (2019).
Eggink, D., Goff, P. H. & Palese, P. Guiding the immune response in opposition to influenza virus hemagglutinin towards the conserved stalk area by hyperglycosylation of the globular head area. J. Virol. 88, 699–704 (2014).
Martinez, D. R. et al. Chimeric spike mRNA vaccines defend in opposition to sarbecovirus problem in mice. Science 373, 991–998 (2021).
Xu, Ok. et al. Protecting prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines in opposition to SARS-CoV-2. Cell 185, 2265–2278 (2022).
Thompson, C. P. et al. A naturally protecting epitope of restricted variability as an influenza vaccine goal. Nat. Commun. 9, 3859 (2018).
Ross, T. M. et al. A computationally designed H5 antigen exhibits immunological breadth of protection and protects in opposition to drifting avian strains. Vaccine 37, 2369–2376 (2019).
Allen, J. D. & Ross, T. M. Bivalent H1 and H3 COBRA recombinant hemagglutinin vaccines elicit seroprotective antibodies in opposition to H1N1 and H3N2 influenza viruses from 2009 to 2019. J. Virol. 96, e0165221 (2022).
Allen, J. D. & Ross, T. M. Subsequent era methodology for updating HA vaccines in opposition to rising human seasonal influenza A(H3N2) viruses. Sci. Rep. 11, 4554 (2021).
Carnell, G. et al. Glycan masking of a non-neutralising epitope enhances neutralising antibodies focusing on the RBD of SARS-CoV-2 and its variants. Entrance. Immunol. 14, 1118523 (2023).
Vishwanath, S. et al. A computationally designed antigen eliciting broad humoral responses in opposition to SARS-CoV-2 and associated sarbecoviruses. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01094-2 (2023).
Fries, C. N. et al. Advances in nanomaterial vaccine methods to handle infectious ailments impacting world well being. Nat. Nanotechnol. 16, 1–14 (2021).
Kanekiyo, M. et al. Mosaic nanoparticle show of various influenza virus hemagglutinins elicits broad B-cell responses. Nat. Immunol. 20, 362–372 (2019).
Yuan, Y. et al. A bivalent nanoparticle vaccine reveals potent cross-protection in opposition to the variants of SARS-CoV-2. Cell Rep. 38, 110256 (2022).
Chen, R. et al. Improvement of receptor binding area (RBD)‐conjugated nanoparticle vaccines with broad neutralization in opposition to SARS‐CoV‐2 Delta and different variants. Adv. Sci. (Weinh.) 9, 2105378 (2022).
Geng, Q. et al. Novel virus-like nanoparticle vaccine successfully protects animal mannequin from SARS-CoV-2 an infection. PLoS Pathog. 17, e1009897 (2021).
Ueda, G. et al. Tailor-made design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. eLife 9, e57659 (2020).
Boyoglu-Barnum, S. et al. Quadrivalent influenza nanoparticle vaccines induce broad safety. Nature 592, 623–628 (2021).
SK Bioscience and GSK’s adjuvanted COVID-19 vaccine candidate meets coprimary goals in a part III examine; biologics license software submitted for SKYCovioneTM (GBP510/GSK adjuvant) in South Korea. GSK (29 April 2022); https://www.gsk.com/en-gb/media/press-releases/sk-bioscience-and-gsk-s-adjuvanted-covid-19-vaccine-candidate-meets-coprimary-objectives-in-a-phase-iii-study/
Partitions, A. C. et al. Elicitation of broadly protecting sarbecovirus immunity by receptor-binding area nanoparticle vaccines. Cell 184, 5432–5447 (2021).
Kang, Y.-F. et al. Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects in opposition to an infection of SARS-CoV-2 variants. Nat. Commun. 13, 2674 (2022).
Bruun, T. U. J., Andersson, A.-M. C., Draper, S. J. & Howarth, M. Engineering a rugged nanoscaffold to boost plug-and-display vaccination. ACS Nano 12, 8855–8866 (2018).
Rahikainen, R. et al. Overcoming symmetry mismatch in vaccine nanoassembly by way of spontaneous amidation. Angew. Chem. Int. Ed. 60, 321–330 (2021).
Cohen, A. A. et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science 371, 735–741 (2021).
Cohen, A. A. et al. Mosaic RBD nanoparticles defend in opposition to problem by various sarbecoviruses in animal fashions. Science 377, eabq0839 (2022).
Hills, R. A. et al. Multiviral quartet nanocages elicit broad anti-coronavirus responses for proactive vaccinology. Preprint at https://doi.org/10.1101/2023.02.24.529520 (2023).
Zuccarino-Catania, G. V. et al. CD80 and PD-L2 outline functionally distinct reminiscence B-cell subsets which might be impartial of antibody isotype. Nat. Immunol. 15, 631–637 (2014).
McGrath, J. J. C., Li, L. & Wilson, P. C. Reminiscence B cell range: insights for optimized vaccine design. Tendencies Immunol. 43, 343–354 (2022).
Chan, T. D. et al. Elimination of germinal-center-derived self-reactive B cells is ruled by the situation and focus of self-antigen. Immunity 37, 893–904 (2012).
Shokat, Ok. M. & Goodnow, C. C. Antigen-induced B-cell demise and elimination throughout germinal-centre immune responses. Nature 375, 334–338 (1995).
Pulendran, B., Kannourakis, G., Nouri, S., Smith, Ok. G. & Nossal, G. J. Soluble antigen may cause enhanced apoptosis of germinal-centre B cells. Nature 375, 331–334 (1995).
Silva, M. et al. Focused elimination of immunodominant B cells drives the germinal middle response towards subdominant epitopes. Cell Rep. 21, 3672–3680 (2017).
Meyer-Hermann, M. Injection of antibodies in opposition to immunodominant epitopes tunes germinal facilities to generate broadly neutralizing antibodies. Cell Rep. 29, 1066–1073 (2019).
Angeletti, D. et al. Outflanking immunodominance to focus on subdominant broadly neutralizing epitopes. Proc. Natl Acad. Sci. USA 116, 13474–13479 (2019).
Liu, H. et al. Construction-based programming of lymph-node focusing on in molecular vaccines. Nature 507, 519–522 (2014).
Caminschi, I. & Shortman, Ok. Boosting antibody responses by focusing on antigens to dendritic cells. Tendencies Immunol. 33, 71–77 (2012).
Kim, J. H., Davis, W. G., Sambhara, S. & Jacob, J. Methods to alleviate unique antigenic sin responses to influenza viruses. Proc. Natl Acad. Sci. USA 109, 13751–13756 (2012).
Netea, M. G. et al. Defining educated immunity and its position in well being and illness. Nat. Rev. Immunol. 20, 375–388 (2020).
Koutsakos, M. & Ellebedy, A. H. Immunological imprinting: understanding COVID-19. Immunity 56, 909–913 (2023).
Monge, S., Pastor-Barriuso, R. & Hernán, M. A. The imprinting impact of COVID-19 vaccines: an anticipated choice bias in observational research. Brit. Med. J. 381, e074404 (2023).
Barda, N. The ups and downs of observational vaccine analysis. Lancet Infect. Dis. 23, 767–768 (2023).
Yisimayi, A. et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Preprint at https://doi.org/10.1101/2023.05.01.538516 (2023).
Nuñez, N. G. et al. Excessive-dimensional evaluation of 16 SARS-CoV-2 vaccine mixtures reveals lymphocyte signatures correlating with immunogenicity. Nat. Immunol. 24, 941–954 (2023).
Muik, A. et al. Progressive lack of conserved spike protein neutralizing antibody websites in Omicron sublineages is balanced by preserved T cell immunity. Cell Rep. 42, 112888 (2023).
Inoue, T. & Kurosaki, T. Reminiscence B cells. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-023-00897-3 (2023).
Mohammed, R. N. et al. A complete overview about immune responses and exhaustion throughout coronavirus illness (COVID-19). Cell Commun. Sign. 20, 79 (2022).
Ferreira-Gomes, M. et al. SARS-CoV-2 in extreme COVID-19 induces a TGF-β-dominated continual immune response that doesn’t goal itself. Nat. Commun. 12, 1961 (2021).
Pušnik, J. et al. Reminiscence B cells focusing on SARS-CoV-2 spike protein and their dependence on CD4+ T cell assist. Cell Rep. 35, 109320 (2021).
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.